Sara Margolin
Overview
Explore the profile of Sara Margolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
9798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
2.
Vermani L, Barnekow E, Liu W, Wendt C, Hall P, Margolin S, et al.
Genes (Basel)
. 2025 Jan;
15(12.
PMID: 39766883
To find support for risk-modifying genes in breast cancer, a haplotype GWAS in sporadic breast cancer cases was undertaken. The results were compared with the results from previous analyses in...
3.
Zanti M, OMahony D, Parsons M, Li H, Dennis J, Aittomakkiki K, et al.
Hum Mutat
. 2024 May;
2023.
PMID: 38725546
A large number of variants identified through clinical genetic testing in disease susceptibility genes, are of uncertain significance (VUS). Following the recommendations of the American College of Medical Genetics and...
4.
Grassmann F, Malarstig A, Dahl L, Bendes A, Dale M, Thomas C, et al.
Br J Cancer
. 2023 Dec;
130(4):620-627.
PMID: 38135714
Objective: Current breast cancer risk prediction scores and algorithms can potentially be further improved by including molecular markers. To this end, we studied the association of circulating plasma proteins using...
5.
Muranen T, Morra A, Khan S, Barnes D, Bolla M, Dennis J, et al.
NPJ Breast Cancer
. 2023 May;
9(1):37.
PMID: 37173335
We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of...
6.
Barnekow E, Hasslow J, Liu W, Bryant P, Thutkawkorapin J, Wendt C, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901898
Most breast cancer heritability is unexplained. We hypothesized that analysis of unrelated familial cases in a GWAS context could enable the identification of novel susceptibility loci. In order to examine...
7.
Thoren L, Margolin S, Eliasson E, Bergh J, Lindh J
Breast Cancer Res Treat
. 2023 Mar;
198(3):499-508.
PMID: 36856936
Purpose: Suboptimal adherence to adjuvant endocrine treatment (AET) is an important clinical concern. A correlation between CYP2D6 activity and tamoxifen discontinuation has been described. The main aim of this study...
8.
Morra A, Mavaddat N, Muranen T, Ahearn T, Allen J, Andrulis I, et al.
Am J Hum Genet
. 2023 Feb;
110(3):475-486.
PMID: 36827971
Evidence linking coding germline variants in breast cancer (BC)-susceptibility genes other than BRCA1, BRCA2, and CHEK2 with contralateral breast cancer (CBC) risk and breast cancer-specific survival (BCSS) is scarce. The...
9.
Sund M, Garmo H, Andersson A, Margolin S, Ahlgren J, Valachis A
Breast Cancer Res Treat
. 2023 Feb;
198(2):361-368.
PMID: 36773184
Purpose: The safety of local estrogen therapy in patients on adjuvant endocrine treatment is questioned, but evidence on the issue is scarce. This nested case-control registry-based study aimed to investigate...
10.
Figlioli G, Billaud A, Ahearn T, Antonenkova N, Becher H, Beckmann M, et al.
Eur J Hum Genet
. 2023 Jan;
31(5):578-587.
PMID: 36707629
Evidence from literature, including the BRIDGES study, indicates that germline protein truncating variants (PTVs) in FANCM confer moderately increased risk of ER-negative and triple-negative breast cancer (TNBC), especially for women...